Patents by Inventor Marie-Pierre Dubé

Marie-Pierre Dubé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT
    Publication number: 20230151424
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: June 16, 2022
    Publication date: May 18, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • CETP inhibitors for therapeutic use
    Patent number: 11549142
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • METHODS FOR USING LOW-DOSE COLCHICINE AFTER MYOCARDIAL INFARCTION
    Publication number: 20220401388
    Abstract: The invention features methods of treating a patient after having a myocardial infarction including administering colchicine to a patient determined to have a genetic variant in the genome that is indicative of the patient benefiting from colchicine administration or not to have a genetic variant in the genome that is that is indicative of the patient suffering a gastrointestinal disorder following colchicine administration.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 22, 2022
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF
  • Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
    Patent number: 11401554
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: August 2, 2022
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20210290623
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 23, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
    Publication number: 20210236442
    Abstract: The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 5, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Fouzia LAGHRISSI-THODE
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT
    Publication number: 20200239960
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20200222406
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • CETP inhibitors for therapeutic use
    Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
    Patent number: 10584385
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
    Publication number: 20190070178
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 7, 2019
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20180155784
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Dalcetrapib for therapeutic use
    Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT
    Publication number: 20170233812
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 25, 2017
    Publication date: August 17, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY
    Publication number: 20160244826
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 25, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • GENOTYPING TESTS AND METHODS FOR EVALUATING PLASMA CREATINE KINASE LEVELS
    Publication number: 20160230231
    Abstract: The invention relates to genetic variants useful for evaluating creatine kinase levels in a subject and determining an Nupper limit of normal (ULN) CK level for a subject. ULN CK level is used in determining the pathological significance of measures of blood or plasma CK obtained from the subject. The methods and compositions of the invention are useful for providing a genetic-C ally determined or individualized ULN CK level, for diagnosing statin-induced myopathy and for providing statin therapy.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 11, 2016
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy
    Patent number: 8563241
    Abstract: There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: October 22, 2013
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Marie-Pierre Dubé, Hannah Beattie
  • Mutations in human UBIAD1
    Patent number: 8334369
    Abstract: The invention relates to polynucleotides and polypeptides which encode UBIAD1.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: December 18, 2012
    Assignee: Genome Atlantic
    Inventors: Mark Elliot Samuels, Duane Guernsey, Marie-Pierre Dube, Andrew C. Orr